The HIRA has changed the chemotherapy benefit standard, four criteria are changed and three criteria are deleted in relation to pancreatic cancer chemotherapy. Changes are made in a total of 25 criteria.

The HIRA recently prepared an amendment to 'Details on the Standards and Methods of Applying Medical Care Benefits to Drugs Prescribed and Administered to Cancer Patients.'

As a result, the standard for chemotherapy was improved sequentially, and the standard for chemotherapy related to small cell lung cancer, esophageal cancer, thyroid cancer, hepatobiliary cancer, and head and neck cancer was changed. The chemotherapy for which the reimbursement standard is changed this time is for panc